Stonebridge Pharma and Capellon Pharmaceuticals Announce Co-Promotion Agreement to Market Symax(TM) Duotab (hyoscyamine sulfate) for Irritable Bowel Syndrome.
Business Wire › October 11, 2006
Linked as:
Business Wire › October 11, 2006
Linked as:Extract
Stonebridge Pharma and Capellon Pharmaceuticals Announce Co-Promotion Agreement to Market Symax(TM) Duotab (hyoscyamine sulfate) for Irritable Bowel Syndrome.
Proven IBS Medication to Be Offered in Unique Dosage Form
DULUTH, Ga. -- StoneBridge Pharma, LLC of Duluth, Georgia and Capellon Pharmaceuticals of Fort Worth, Texas, have announced a co-promotion agreement to market Capellon's adjunctive treatment for irritable bowel syndrome (IBS...See the full content of this document
Sponsored links
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other documents:
ADVISORY/Commemorative Capitol Corridor Train Ride Planned. | Customer-owned utility profits from technology, planning. | schnitzer steel board declares quarterly dividend. | sentencia nº 2700 de consiglio di stato june 01 2009 | sentencia nº 243 de consiglio di stato january 24 2011 | Sentencia nº 3094 de Consiglio di Stato July 20 2011 | sentencia nº 3222 de consiglio di stato july 14 2010